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Abstract
Objective:  The objective of this study was to compare intramuscular (IM) ziprasidone to
conventional IM medications (haloperidol combined with lorazepam) for the treatment of severe
agitation in adolescents (age 12–17).
Methods:  We retrospectively identified consecutive severe agitation episodes (defined as
requiring physical restraint) in adolescents treated with either IM ziprasidone or conventional IM
agents in a psychiatric emergency room. For ziprasidone, the dosage was 20 mg for 23 episodes
and 10 mg for 5 episodes. For 24 episodes treated with combined haloperidol and lorazepam, the
dosages were 4.8 ± 0.3 SEM mg and 1.9 ± 0.4 mg respectively. Outcomes were the duration of
restraint and need for adjunctive "rescue" medications within 60 minutes. These outcomes were
decided prior to reviewing any records.
Results: No difference was found in restraint duration (ziprasidone, N = 28, 55 ± 5 minutes;
haloperidol with lorazepam N = 24, 65 ± 7 minutes, P = NS). Use of "rescue" medications did not
differ between the two groups. No changes in blood pressure were found, but pulse decreased 8.3
± 2.4 for haloperidol with lorazepam and 8.9 ± 4.24 for ziprasidone (P = NS). No instances of
excessive sedation or extra-pyramidal symptoms were documented.
Conclusion: In this study, IM ziprasidone appeared effective, well tolerated, and similar in clinical
profile to combined conventional IM medications for treating severe agitation in adolescents. Given
the reportedly favorable acute side effect profile of parenteral atypical agents, they may provide an
alternative to conventional antipsychotics for treating acute agitation in both adult and adolescent
populations. Future randomized, controlled studies are needed.
Background
Patients with agitation commonly present to psychiatric
emergency services [PES]. Sedatives and mechanical
restraints have been mainstays of treatment for severe agi-
tation. As use of restraints is under increasing scrutiny
because of potential increased morbidity and mortality,
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rapid and effective pharmacological management of
severe agitation is critical [1].
Oral medication can be impractical or impossible in
severe agitation. Conventional IM first-generation antip-
sychotics given as monotherapy or combined with
lorazepam are commonly used. These agents may be asso-
ciated with adverse effects, e.g. dystonia and other extra-
pyramidal symptoms with haloperidol, and excess seda-
tion with benzodiazepines [2].
Atypical antipsychotics have gained acceptance as first-
line treatment for psychotic disorders. These agents have
shown greater efficacy in some studies and a more favora-
ble acute side effect profile. Currently, risperidone is indi-
cated for the treatment of schizophrenia in adolescents
age 13–17 years, bipolar mania in children and adoles-
cents age 10–17 years, and irritability associated with
autistic disorder in children and adolescents age 5–16.
Aripiprazole is indicated for schizophrenia in children
and adolescents age 13–17 years and bipolar mania in
children and adolescents age 10–17 years. Several recent
studies have described results of oral atypical antipsychot-
ics in pediatric populations with a variety of diagnoses,
e.g., ziprasidone for Tourette's disorder [3], risperidone
for autistic disorder [4], olanzapine for bipolar mania [5],
and aripiprazole for schizophrenia [6]. In general, these
studies show positive clinical benefits.
Based on a combination of evidence- and consensus-
based methodologies, a recent expert panel addressing
treatment in children and adolescents recommended an
expanded role for atypical antipsychotics, stating "Recom-
mendation 5: Use an atypical antipsychotic first rather
than a typical antipsychotic to treat aggression" [7]. The
recommendation specifically included a broader range of
diagnoses stating, "When psychosocial and first-line med-
ication treatments for primary non-psychotic conditions
have failed, physicians initially should use first-line atyp-
ical (rather than typical) antipsychotic medications to
treat severe and persistent aggression" (Pappadopulos et
al., 2003, p.151). The rationale for recommending atypi-
cal antipsychotics was principally their more favorable
acute side-effect profile compared to older agents such as
haloperidol (when used alone).
Ziprasidone was the first atypical antipsychotic agent
available in parenteral form. In clinical trials for agitation
in adults with psychotic disorders, it showed clinical effect
within 15–30 minutes [8,9]. It was well tolerated with a
low incidence of dystonia and EPS, and not found to pro-
duce oversedation. Despite a more favorable acute side-
effect profile compared to older agents, it is associated
with risk of QTC prolongation and a potential for arrhyth-
mias [10]. Clinical trials of IM ziprasidone excluded chil-
dren and adolescents, patients with severe agitation, and
those whose agitation was associated with substance
abuse.
Evidence is emerging from some studies that parenteral
atypical antipsychotics may be useful in treating children
and adolescents. Four retrospective studies have been
published on IM ziprasidone for agitated adolescents [11-
14], but none were conducted in a PES setting or com-
pared ziprasidone to haloperidol. All four studies indi-
cated positive clinical benefits without serious adverse
effects.
As part of a naturalistic, retrospective observational study
of IM ziprasidone versus conventional IM sedatives in agi-
tated patients in the PES at SUNY Stony Brook, we
obtained data on 110 adults receiving IM ziprasidone
[15,16]. We found IM ziprasidone worked more quickly
than in the published clinical trials, and that is was effec-
tive for agitation associated with substance abuse. During
this naturalistic, retrospective observational study, we also
treated 28 adolescents with IM ziprasidone and 24 adoles-
cents with conventional IM sedatives.
Methods
PES Background
The SUNY Stony Brook PES receives ~6800 cases annu-
ally. Approximately 80% of patients present with major
psychiatric illness and/or alcohol- or substance-induced
intoxication. Approximately 60% of patients arrive by
police escort, and 40% are involuntarily admitted after
evaluation. Approximately 50% of patients receive medi-
cation. About 20% of referred cases are children or adoles-
cents (age <18).
Study Design
This was a retrospective, naturalistic outcome, nonran-
dom study (choice of sedative drug was by clinician pref-
erence). The study was approved by the institutional
human subjects committee.
Patients
A search of consecutive restraint records for episodes of
agitation revealed 76 adolescents (age 12–17 years old)
received an IM medication at the time of restraint, from
October 2002 to August 2006. Of these, 24 were excluded:
4 who received ziprasidone with lorazepam, 6 who
received oral or IM sedatives within 1 hour prior, and 14
who received miscellaneous IM agents (diphenhy-
dramine, lorazepam, amobarbital, or chlorpromazine).
No records were found for IM haloperidol monotherapy.
Demographic features of the resulting 2 groups are shown
in Table 1. The most common primary clinical diagnoses
were substance related disorders (N = 7), psychotic disor-Child and Adolescent Psychiatry and Mental Health 2009, 3:9 http://www.capmh.com/content/3/1/9
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ders (N = 7), adjustment disorders (N = 7), and impulse
control disorders (N = 5). Of the 52 patients, 15 were on
no home medications, while 26 were prescribed atypical
antipsychotics, 21 mood stabilizers, 19 antidepressants, 9
stimulants, and 4 miscellaneous. These home medication
types did not differ by group. Positive toxicology was
found in 17/52 cases; the most common agents were can-
nabis (N = 14), benzodiazepines (N = 5), and cocaine (N
= 4). There was no difference in the hospitalization rate
for the 2 groups. In all cases the episode of agitation
resolved. The patients were ambulatory at the time of dis-
charge from the PES or transfer to a psychiatric hospital.
Treatment
Adolescents had received either a single dose of ziprasi-
done 10 mg IM (N = 4) or ziprasidone 20 mg IM (N = 24)
or IM haloperidol (average dose = 4.8 ± 0.3 mg, range 2.5–
10), the latter combined in all cases with IM lorazepam
(average dose = 1.9 ± 0.4 mg, range 1–2) (N = 24).
Restrained patients received medication simultaneously
with initiation of physical restraint. Any additional oral or
parenteral sedative given within the next 1 hour was con-
sidered a rescue medication. Duration of restraint epi-
sodes was obtained from nursing documentation in the
progress notes or the restraint records.
Assessments
Concurrent agitation scores using the Behavioral Activity
Rating Scale (BARS [17], Figure 1) recorded every 15 min-
utes from baseline to 120 minutes were available for 7 of
the ziprasidone subjects and none of the comparison
group. Scores on the BARS range from 1 to 7, where 1 =
difficult or unable to arouse, 2 = asleep but responds nor-
mally to verbal or physical contact, 3 = drowsy, appears
sedated, 4 = quiet and awake (normal level of activity), 5
= signs of overt (physical or verbal) activity, calms down
with instructions, 6 = extremely or continuously active,
not requiring restraint, and 7 = violent, requires restraint.
Data Analyses
Comparisons were made by t-test, ANOVA using repeated




Baseline BARS scores for a subset of adolescents receiving
ziprasidone were initially high and decreased rapidly. A
significant decrease was found at 30 minutes and thereaf-
ter. The initial scores and time course after treatment were
not different from agitated adults in our PES study (Figure
1).
No difference was found in restraint duration (ziprasi-
done N = 28, 55 ± 5 minutes; haloperidol with lorazepam
N = 24, 65 ± 7 minutes, P = NS) as shown in Figure 2. Use
of rescue medications did not differ between ziprasidone
(2/28) and haloperidol combined with lorazepam (1/24)
(χ2 = 0.2, P = 0.6).
Ziprasidone IM was well tolerated in adolescents as
shown in Figure 3. For adolescents, usable blood pressure






Age (years) [SD] 15.5 ± 1.5 15.9 ± 1.2 NS
Gender male/female 12/16 15/9 NS
Police Escort* 16/28 17/24 NS
Toxicology Positive** 7/28 10/24 NS
Psychiatrically Hospitalized 8/28 8/24 NS
*Police Escort = Adolescent was brought to hospital and escorted to PES by police due to violent or uncontrollable behavior.
**Urine toxicologies were often positive for multiple substances. Most common substances were: cannabis N = 14, benzodiazepines N = 5, and 
cocaine N = 4.
Mean Behavioural Activity Rating Scale (BARS) Figure 1
Mean Behavioural Activity Rating Scale (BARS). (1 = 
difficult or unable to arouse; 2 = asleep but responds nor-
mally to verbal or physical contact; 3 = drowsy, appears 
sedated; 4 = quiet and awake [normal level of activity]; 5 = 
signs of overt [physical or verbal] activity, calms down with 
instructions; 6 = extremely or continuously active, not 
requiring restraint; 7 = violent, requires restraint) scores for 
7 adolescent patients after treatment with IM ziprasidone. 
Scores at 30 minutes (p < 0.05) and thereafter (p < 0.01) 
were significantly different from baseline (Tukey test).Child and Adolescent Psychiatry and Mental Health 2009, 3:9 http://www.capmh.com/content/3/1/9
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No difference was found in restraint duration Figure 2
No difference was found in restraint duration. (ziprasidone, N = 28, 55 ± 5 minutes; haloperidol combined with 
lorazepam, N = 24, 66 ± 7; P = NS). Use of rescue medications did not differ between ziprasidone (2/28) and haloperidol com-
bined with lorazepam (1/24).
Blood pressure/heart rate data were available for 18 patients before and after ziprasidone IM and 12 for combined conven- tional agents Figure 3
Blood pressure/heart rate data were available for 18 patients before and after ziprasidone IM and 12 for com-
bined conventional agents. No overall pre-post changes in blood pressure were found, but pulse decreased 8.3 ± 2.4 for 
haloperidol combined with lorazepam and 8.9 ± 4.24 for ziprasidone (P = NS). SYS = systolic blood pressure; DIA = diastolic 
blood pressure; HR = heart rate; PRE = prior to treatment with IM medication; POST = after treatment with IM medication.Child and Adolescent Psychiatry and Mental Health 2009, 3:9 http://www.capmh.com/content/3/1/9
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and heart rate data were available for 18 patients before
and after ziprasidone IM and 12 for combined conven-
tional agents. No overall pre-post changes in blood pres-
sure were found, but pulse decreased 8.3 ± 2.4 for
haloperidol combined with lorazepam and 8.9 ± 4.24 for
ziprasidone (P = NS) (figure 3). Of 28 ziprasidone cases,
4 post treatment ECGs were available and showed normal
QTc (387–451 milliseconds). There were no recorded
extrapyramidal reactions or administrations of anti-
cholinergic agents.
Discussion
The results of this naturalistic, retrospective, observational
study suggest that IM ziprasidone monotherapy may be as
effective for the treatment of severe agitation as combined
IM conventional agents in severely agitated adolescents
presenting to a PES. There was no difference in the dura-
tion of restraints or need for rescue medication between
the two groups. In addition, among 7 unselected episodes
of agitation that were rated on the BARS, there was a rapid
and significant improvement within 30 minutes from ini-
tial high severity scores. Future randomized as well as
observational trials will show whether monotherapy with
ziprasidone has similar efficacy to the combination of
conventional agents haloperidol with lorazepam. How-
ever, consent issues will make prospective trials difficult.
The data represent a naturalistic outcome of unselected
cases that were typical of severely agitated adolescents
who presented to a PES. We defined severe agitation as
episodes requiring physical restraint. Cases were identi-
fied by searching restraint logs. Hence, cases of IM medi-
cation use not requiring restraints were not captured.
Although the samples represented a consecutive case
series, the patients were not randomly assigned to treat-
ment, and the choice of an IM agent for agitation was not
controlled. The possibility of missing documentation of
adverse drug events in this study prevents definitive con-
clusions regarding the safety of these agents in children
and adolescents. Thus the results of this study are tentative
due to the possible methodological limitations, including
potential retrospective biases, lack of more extensive
results from the standardized rating scale of agitation, and
modest sample size.
Although the two treatment groups were identified retro-
spectively, the 28 ziprasidone-treated adolescent patients
in the present analysis were similar in demographics, had
similar proportions of need for rescue medication,
restraint use, and duration of restraint compared to the 24
subjects in the comparison group who received conven-
tional IM agents. These observations suggest that there is
no apparently systematic difference between the two final
groups that would have biased outcome after parenteral
medication. However, as previously stated, modest sam-
ple size may have created false negative findings in regard
to demographic information.
For the subgroup of 7 patients rated on the BARS, symp-
toms of severe agitation were significantly reduced within
30 minutes after a single dose of IM ziprasidone, for up to
120 minutes. The mean baseline BARS score of 6.9,
although high, was not statistically different from that
(6.6 ± 0.1) in the entire adult population of agitated
patients (N = 110) in the original study as well as in a sub-
sample of geriatric agitated patients (6.8 ± 0.1) [15,16].
These scores are similar to those reported by retrospective
ratings of 59 agitated adolescents treated with parenteral
ziprasidone whose scores were 6.5 ± 0.7 [11]. The high
BARS scores in these naturalistic samples suggest that
these studies show more severe agitation than the pub-
lished clinical trials of intramuscular ziprasidone for
adults with schizophrenia where the mean BARS score
was 5.0 [18]. The agitation scores for adolescents showed
similar rates of clinically and statistically significant reduc-
tion at 45 minutes after ziprasidone administration (-
42%), as did the adults in our prior study (-50%). The
BARS is not part of routine care. The 7 patients for whom
BARS data was available had participated in a prior study
[15]
Atypical antipsychotics in the oral formulation have
gained acceptance as first-line treatments for psychosis.
Overall, the atypical neuroleptics have been shown to
have similar effectiveness in available studies and to have
a more favorable acute adverse-effect profile compared
with first-generation antipsychotic agents. Some of these
agents may pose a greater risk for early weight gain and
metabolic consequences when used for ongoing treat-
ment. Few studies of the effects of IM neuroleptics in the
adolescent population are available. Pending randomized
controlled trials, which are not likely to be readily availa-
ble for severe agitation in adolescents, this study and prior
studies suggest that parenteral atypical antipsychotics may
be useful for short-term treatment of severe agitation in
this clinical setting. Oral antipsychotic use after IM antip-
sychotic use was not captured in this study, and so issues
regarding transition to oral medication cannot be
addressed.
Conclusion
The results of this study indicate that reduction in severe
agitation in the ziprasidone IM monotherapy group was
comparable to the haloperidol IM combined with
lorazepam IM group. Clinical outcomes were similar for
time in restraint and need for rescue medications. The
results of this study are tentative but consistent with the
prior literature that ziprasidone IM is safe and well toler-
ated in adolescents. IM atypical antipsychotics such as
ziprasidone offer an emerging alternative to butyrophe-Publish with BioMed Central    and   every 
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nones, benzodiazepines, or their combination for man-
agement of severe agitation.
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